Skip to main content

letter

. 1996 Jan 13;312(7023):121–122. doi: 10.1136/bmj.312.7023.121a

Guidelines for prescribing combined oral contraceptives.

A M Mills, C L Wilkinson, D R Bromham, J Elias, K Fotherby, J Guillebaud, A Kubba, A Wade

PMCID: PMC2349741 PMID: 8555906

122

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Bloemenkamp K. W., Rosendaal F. R., Helmerhorst F. M., Büller H. R., Vandenbroucke J. P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet. 1995 Dec 16;346(8990):1593–1596. doi: 10.1016/s0140-6736(95)91929-5. [DOI] [PubMed] [Google Scholar]
Jick H., Jick S. S., Gurewich V., Myers M. W., Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995 Dec 16;346(8990):1589–1593. doi: 10.1016/s0140-6736(95)91928-7. [DOI] [PubMed] [Google Scholar]
Lewis M. A., Spitzer W. O., Heinemann L. A., MacRae K. D., Bruppacher R., Thorogood M. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ. 1996 Jan 13;312(7023):88–90. doi: 10.1136/bmj.312.7023.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
Spitzer W. O., Lewis M. A., Heinemann L. A., Thorogood M., MacRae K. D. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ. 1996 Jan 13;312(7023):83–88. doi: 10.1136/bmj.312.7023.83. [DOI] [PMC free article] [PubMed] [Google Scholar]

ACTIONS

RESOURCES